Jonathan Zung - Curis Chief Officer
| CRIS Stock | USD 4.03 0.07 1.71% |
Executive
Jonathan Zung is Chief Officer of Curis Inc
| Age | 59 |
| Address | Building C, Lexington, MA, United States, 02421 |
| Phone | 617 503 6500 |
| Web | https://www.curis.com |
Curis Management Efficiency
The company has return on total asset (ROA) of (0.4597) % which means that it has lost $0.4597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.7268) %, meaning that it created substantial loss on money invested by shareholders. Curis' management efficiency ratios could be used to measure how well Curis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2024. Return On Capital Employed is likely to drop to -0.8 in 2024. At this time, Curis' Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 64.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 1.3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Cynthia MD | Leap Therapeutics | 54 | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| RPh PharmD | Affimed NV | 40 | |
| Philippe Ledru | Aptose Biosciences | 56 | |
| Leiv Lea | Corvus Pharmaceuticals | 70 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Andrew Yates | Artelo Biosciences | N/A | |
| Spencer JD | PDS Biotechnology Corp | 54 | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| James MD | Corvus Pharmaceuticals | N/A | |
| Arndt MD | Affimed NV | 58 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Maria Kelman | Pieris Pharmaceuticals | N/A | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
| Shane Olwill | Pieris Pharmaceuticals | 48 | |
Management Performance
| Return On Equity | -3.73 | ||||
| Return On Asset | -0.46 |
Curis Inc Leadership Team
Elected by the shareholders, the Curis' board of directors comprises two types of representatives: Curis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curis. The board's role is to monitor Curis' management team and ensure that shareholders' interests are well served. Curis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Zung, Chief Officer | ||
| Reinhard MD, Senior Development | ||
| Elif McDonald, VP Communications | ||
| James Dentzer, CFO, Chief Administrative Officer, Treasurer, Secretary | ||
| Mark Noel, Vice Property |
Curis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Curis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.73 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 17.12 M | ||||
| Shares Outstanding | 8.47 M | ||||
| Shares Owned By Insiders | 6.77 % | ||||
| Shares Owned By Institutions | 24.36 % | ||||
| Number Of Shares Shorted | 137.03 K | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 4.32 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curis Stock Analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.